Beta Bionics, Inc. (BBNX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Beta Bionics, Inc. (BBNX) trades at $17.20 with AI Score 28/100 (Grade F). Beta Bionics, Inc. is a commercial-stage medical device company focused on developing and commercializing solutions for people with diabetes. Market cap: $766.24M, Sector: Healthcare.
Price live · AI analysis from May 9, 2026BBNX stock analysis for 2026: Analysts have set a consensus price target of $25.18 for Beta Bionics, Inc., suggesting 46.4% upside from the current price of $17.20. The AI MoonshotScore is 28/100, indicating a bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
BBNX: 4/4 perspectives are bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Beta Bionics, Inc. (BBNX) Healthcare & Pipeline Overview
Beta Bionics, Inc. develops and commercializes medical devices for diabetes management, primarily the iLet Bionic Pancreas, an insulin delivery system for type 1 diabetes. With a focus on automated insulin delivery, the company aims to improve the health and quality of life for insulin-requiring individuals, competing in the medical equipment and services sector.
What Is the Investment Thesis for BBNX?
Beta Bionics presents a notable research candidate within the diabetes management space, driven by its innovative iLet Bionic Pancreas system. The company's focus on automated insulin delivery addresses a significant unmet need for individuals with type 1 diabetes, potentially leading to strong market adoption. Key value drivers include the expansion of iLet's user base, successful development and commercialization of pipeline products like the Patch Pump and Bihormonal iLet, and strategic partnerships to enhance its technology and market reach. The company's gross margin of 57.2% indicates a solid foundation for profitability as sales scale. However, potential risks include competition from established players, regulatory hurdles, and the company's current negative profit margin of -60.3%, indicating a need for efficient cost management as it grows.
Based on FMP financials and quantitative analysis
BBNX Key Highlights
- Market Cap of $766.24M reflects investor valuation of Beta Bionics' potential in the diabetes management market.
- Gross Margin of 57.2% indicates strong pricing power and efficient production costs for the iLet Bionic Pancreas.
- Profit Margin of -60.3% highlights the company's current focus on growth and investment in R&D and commercialization.
- Beta of 5.06 suggests high volatility relative to the market, reflecting the growth stage of the company.
- No Dividend Yield indicates that the company is reinvesting earnings for future growth.
Who Are BBNX's Competitors?
BBNX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| TERN Terns Pharmaceuticals, Inc. | $52.95 | -0.03% | $4.77B | 51 |
| FEDDX Fidelity Emerging Markets Discovery Fd | $23.32 | +1.83% | $1.53B | 47 |
| DAUG FT Vest U.S. Equity Deep Buffer ETF - August | $47.01 | +0.09% | $363.75M | 47 |
| KSTR KraneShares SSE STAR Market 50 Index ETF | $28.60 | +0.25% | $66.71M | 47 |
| PEQSX Putnam Large Cap Value Fund | $44.15 | +0.46% | $51.63B | 47 |
| FTQGX Fidelity Focused Stock Fund | $48.84 | +1.67% | $5.50B | 44 |
| FIRRX Fidelity Simplicity RMD 2010 Fund | $51.74 | -0.75% | $9.46M | 44 |
| SHAPX ClearBridge Appreciation A | $36.87 | +0.63% | $9.85B | 44 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BBNX's Key Strengths?
- Innovative iLet Bionic Pancreas technology.
- Strategic partnerships with Xeris and Abbott.
- Focus on automated insulin delivery.
- Strong gross margin of 57.2%.
What Are BBNX's Weaknesses?
- Negative profit margin of -60.3%.
- Limited product portfolio concentrated on diabetes management.
- Reliance on regulatory approvals for new products.
- High beta of 5.06 indicating high volatility.
What Could Drive BBNX Stock Higher?
- Regulatory approval and launch of the Patch Pump.
- Expansion of iLet Bionic Pancreas sales and market share.
- Progress in the development of the Bihormonal iLet.
- Strategic partnerships and collaborations to enhance product offerings.
What Are the Key Risks for BBNX?
- Negative return on equity (-23.0%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Competition from established medical device companies.
- Regulatory hurdles and delays in product approvals.
- Reimbursement challenges from healthcare payers.
- Negative profit margin requiring efficient cost management.
- High beta indicating high stock price volatility.
What Are the Growth Opportunities for BBNX?
- Expansion of iLet Bionic Pancreas User Base: The primary growth opportunity lies in expanding the user base of the iLet Bionic Pancreas. The global market for insulin delivery devices is estimated to reach billions of dollars, with a significant portion attributed to insulin pumps and automated systems. By increasing awareness, improving user experience, and securing favorable reimbursement policies, Beta Bionics can capture a larger share of this market. Timeline: Ongoing.
- Development and Commercialization of Patch Pump: The development and commercialization of the Patch Pump represent another significant growth opportunity. This tubeless insulin pump offers increased convenience and discretion for users, potentially attracting a new segment of the market. Successful launch and adoption of the Patch Pump could drive revenue growth and enhance Beta Bionics' product portfolio. Timeline: Within the next 2-3 years.
- Bihormonal iLet Development: The Bihormonal iLet, which combines automated insulin and glucagon delivery, holds promise for improved glucose control and reduced risk of hypoglycemia. Successful development and regulatory approval of this device could establish Beta Bionics as a leader in advanced diabetes management solutions. The market for bihormonal therapies is nascent but expected to grow as the benefits become more evident. Timeline: Within the next 3-5 years.
- Expansion into Type 2 Diabetes Market: Extending the iLet technology to individuals with insulin-dependent type 2 diabetes represents a substantial growth opportunity. The type 2 diabetes population is significantly larger than the type 1 population, offering a broader market for Beta Bionics' products. Adapting the iLet system for type 2 diabetes could drive significant revenue growth. Timeline: Within the next 3-5 years.
- Strategic Partnerships and Collaborations: Continued strategic partnerships and collaborations with companies like Xeris and Abbott can accelerate product development, expand market reach, and enhance Beta Bionics' technology platform. These partnerships can provide access to complementary technologies, distribution channels, and expertise, driving long-term growth and innovation. Timeline: Ongoing.
What Opportunities Does BBNX Have?
- Expansion into the type 2 diabetes market.
- Development and commercialization of the Patch Pump and Bihormonal iLet.
- Increased adoption of automated insulin delivery systems.
- Growing global diabetes prevalence.
What Threats Does BBNX Face?
- Competition from established medical device companies.
- Regulatory hurdles and delays.
- Reimbursement challenges from healthcare payers.
- Technological advancements from competitors.
What Are BBNX's Competitive Advantages?
- Proprietary iLet Bionic Pancreas technology with automated insulin delivery.
- Strategic partnerships with Xeris and Abbott.
- Focus on innovation in diabetes management solutions.
- Potential for expansion into the type 2 diabetes market.
What Does BBNX Do?
Beta Bionics, Inc., founded in 2015 and based in Irvine, California, is a commercial-stage medical device company dedicated to designing, developing, and commercializing innovative solutions for individuals with diabetes. The company's flagship product is the iLet Bionic Pancreas, an insulin delivery device approved for use in adults and children six years of age and older with type 1 diabetes. This system automates insulin delivery, aiming to simplify diabetes management and improve glycemic control. Beyond the iLet Bionic Pancreas, Beta Bionics is actively developing other products, including the Patch Pump, a discreet, tubeless insulin pump designed for ease of use. The company is also working on the Bihormonal iLet, which combines automated delivery of both insulin and glucagon, potentially offering more comprehensive glucose management. Additionally, Beta Bionics is exploring the application of its iLet technology for individuals with insulin-dependent type 2 diabetes, expanding its potential market reach. Beta Bionics has established strategic collaborations to enhance its product offerings, including agreements with Xeris Pharmaceuticals, Inc. to develop and commercialize a pump-compatible glucagon formulation, and with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system.
What Products and Services Does BBNX Offer?
- Develop and commercialize the iLet Bionic Pancreas, an automated insulin delivery system.
- Offer a solution for managing type 1 diabetes in adults and children.
- Develop the Patch Pump, a tubeless insulin pump for convenient insulin delivery.
- Work on the Bihormonal iLet, combining insulin and glucagon delivery for enhanced glucose control.
- Collaborate with Xeris Pharmaceuticals to develop a pump-compatible glucagon formulation.
- Partner with Abbott Diabetes Care to develop an automated insulin delivery system.
- Focus on improving the health and quality of life for people with diabetes.
How Does BBNX Make Money?
- Sales of the iLet Bionic Pancreas device.
- Recurring revenue from consumables, such as insulin cartridges.
- Partnerships and collaborations with pharmaceutical and medical device companies.
- Future revenue from the Patch Pump and Bihormonal iLet devices.
What Industry Does BBNX Operate In?
Beta Bionics operates in the medical device industry, specifically within the diabetes management sector. The market for diabetes care is substantial and growing, driven by the increasing prevalence of diabetes globally. The competitive landscape includes established medical device companies and emerging players focused on innovative technologies like continuous glucose monitoring (CGM) and automated insulin delivery (AID) systems. Beta Bionics' iLet Bionic Pancreas positions it within the AID segment, which is expected to see significant growth as users seek more convenient and effective diabetes management solutions.
Who Are BBNX's Key Customers?
- Individuals with type 1 diabetes.
- Adults and children (6 years and older) requiring insulin therapy.
- Healthcare providers and diabetes clinics.
- Hospitals and endocrinology centers.
Net buyingInsider Activity
Over the past six months, Beta Bionics, Inc. insiders filed 27 SEC Form 4 transactions — 14 sales and 13 purchases. On net that is roughly 894K shares acquired (about $8.6M) — insiders putting money in tends to read as conviction.
FY2026 estForward Outlook
Wall Street analysts project Beta Bionics, Inc. revenue of about $133.7M for fiscal 2026, with EPS near $-2.18. The estimate reflects 8 contributing analysts.
F-Score 2/9Financial Health
Beta Bionics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 12.26 places it in the safe zone, indicating low near-term bankruptcy risk.
ROE -23%Key Financial Metrics
Return on equity for Beta Bionics, Inc. stands at -23.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -21.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -10.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 10.69 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -10.9%, the inverse of the P/E and a quick read on earnings relative to price.
Beta Bionics, Inc. (BBNX) Valuation Context
Valued at $766.24M, BBNX is classified as a small-cap stock. Relative to its peer group, BBNX's quantitative score of 28/100 is below the peer average of 48/100.
BBNX Revenue & Earnings Trend
In Q1 2026, BBNX generated $27.6M in top-line revenue, marking a sequential decrease of 14.0%. The company recorded a net loss of $21.9M, with diluted EPS of $-0.49. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, BBNX averaged $-0.38 in diluted EPS.
Company Profile
Beta Bionics, Inc. operates in the Medical - Equipment & Services industry within the Healthcare sector. It is headquartered in Irvine, US. The company is led by CEO Sean T. Saint. BBNX has traded publicly since 2025.
BBNX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- BBNX insiders seem to be holding steady, signaling confidence from those who know the company best.
- The buzz in the community is definitely leaning towards excitement about their innovative medical device. People see real potential.
- Beta Bionics is capturing attention as a disruptor in diabetes management. The market loves a good underdog story.
- There's a growing narrative that BBNX is solving a real-world problem, which is resonating with socially conscious investors.
Bear Case
- The medical device space is fiercely competitive. BBNX needs to prove it can stand out from established players.
- Despite the hype, some community members are questioning the long-term viability of their business model.
- Market perception can shift quickly. One negative news cycle could easily turn the tide against BBNX.
- Insider activity, while stable, doesn't show aggressive buying, suggesting a wait-and-see approach even internally.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $28M | -$22M | -$0.49 |
| Q4 2025 | $32M | -$13M | -$0.30 |
| Q3 2025 | $27M | -$14M | -$0.33 |
| Q2 2025 | $23M | -$17M | -$0.39 |
Based on FMP financials and quantitative analysis
BBNX Latest News
-
Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders
prnewswire.com · Jun 22, 2026
-
Johnson Fistel Continues Investigation of Beta Bionics, Inc. (BBNX)
gurufocus.com · Jun 15, 2026
-
Beta Bionics Announces Near Real-Time Real-World Data On iLet Bionic Pancreas Is Now Publicly Available At betabionics.com/hcp/real-world-data
benzinga · Jun 2, 2026
-
Beta Bionics First in Automated Insulin Delivery to Publish Near Real-Time Real-World Data on a Public Website
Yahoo! Finance: BBNX News · Jun 2, 2026
BBNX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BBNX.
Price Targets
Consensus target: $25.18
BBNX MoonshotScore
What does this score mean?
The MoonshotScore rates BBNX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders
Johnson Fistel Continues Investigation of Beta Bionics, Inc. (BBNX)
Beta Bionics Announces Near Real-Time Real-World Data On iLet Bionic Pancreas Is Now Publicly Available At betabionics.com/hcp/real-world-data
Beta Bionics First in Automated Insulin Delivery to Publish Near Real-Time Real-World Data on a Public Website
Leadership: Sean T. Saint
Unknown
Information on Sean T. Saint's background is not available within the provided context. Without additional data, a comprehensive career history, education, and previous roles cannot be accurately detailed. Further research would be required to provide a complete profile.
Track Record: Information on Sean T. Saint's track record is not available within the provided context. Key achievements, strategic decisions, and company milestones under their leadership cannot be accurately detailed without additional data. Further research would be required to provide a complete profile.
BBNX Healthcare Stock FAQ
What does Beta Bionics, Inc. do?
Beta Bionics, Inc. is a medical device company focused on developing and commercializing innovative solutions for people with diabetes. Its primary product is the iLet Bionic Pancreas, an automated insulin delivery system designed to simplify diabetes management and improve glycemic control for individuals with type 1 diabetes. The company is also developing other products, including a tubeless patch pump and a bihormonal system that delivers both insulin and glucagon, aiming to provide comprehensive diabetes management solutions.
What are the main risks for BBNX?
The main risks for BBNX include competition from established medical device companies, regulatory hurdles and potential delays in product approvals, and reimbursement challenges from healthcare payers. The company's current negative profit margin also poses a risk, requiring efficient cost management and revenue growth to achieve profitability. Additionally, the high beta of the stock suggests high volatility, which could impact investor returns.
How does Beta Bionics, Inc. navigate regulatory approval processes?
Beta Bionics, Inc. navigates regulatory approval processes, primarily with the FDA, by conducting rigorous clinical trials to demonstrate the safety and efficacy of its medical devices, such as the iLet Bionic Pancreas. The company compiles comprehensive documentation, including clinical data, manufacturing processes, and risk assessments, to support its submissions. Maintaining compliance with FDA regulations and proactively addressing any concerns raised by the agency are critical to securing timely approvals for its products.
How does Beta Bionics, Inc. manage patent expiration risks?
Beta Bionics, Inc. manages patent expiration risks by continuously innovating and developing new products and technologies to expand its intellectual property portfolio. The company actively seeks patent protection for its inventions to maintain a competitive advantage. Additionally, Beta Bionics may pursue strategic collaborations and licensing agreements to access complementary technologies and extend the lifecycle of its existing products. Diversifying its product pipeline and focusing on next-generation solutions are key strategies for mitigating patent expiration risks.
What are the key factors to evaluate for BBNX?
Beta Bionics, Inc. (BBNX) holds an AI score of 28/100 (low). Analysts target $25.18 (+46%). Not financial advice.
How frequently does BBNX data refresh on this page?
BBNX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven BBNX's recent stock price performance?
Beta Bionics, Inc. (BBNX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative iLet Bionic Pancreas technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BBNX overvalued or undervalued right now?
Valuing Beta Bionics, Inc. (BBNX) requires multiple metrics. Analysts target $25.18 (+46%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may not reflect all aspects of the company.
- Analyst opinions and future projections are subject to change.